David Hutton

Data in early-stage patients was presented at 42nd American Society of Retina Specialists Annual Scientific Meeting, being held in Stockholm, Sweden.

The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

The company’s Spectralis OCTA module with SHIFT technology offers a tool for the diagnoses and management of retinal diseases.

EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage.

Researchers from the UKB Eye Clinic, in cooperation with the University of Bonn and in close collaboration with basic and clinical scientists, have examined patients with early forms of AMD. The researchers focused on the so-called iRORA lesions, which are very early anatomical signs of retinal damage.

Researchers, led by Shigemi Matsuyama, PhD, will conduct research seeking a potential breakthrough drug that can be taken orally—one that may address many RP disease manifestations, regardless of the underlying genetic mutation.

The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.

Ophthalmologist receives the Roger Steinert, MD, Legacy Award during the Octane Ophthalmology Tech Forum in Irvine, California.

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD.

The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody for the treatment of wet AMD, DME and RVO.

VUMC noted that the diagnosis of diabetes and treatment needed to prevent diabetes complications may be delayed in people who carry the variant, G6PDdef.

According to the company, the acquisition includes 2 commercial assets Iluvien and Yutiq, expanding ANI’s foothold in ophthalmology.

The results were presented at a symposium during the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, and mark the first large-scale trial specifically designed to investigate the effect of fenofibrate on eye outcomes in people with early diabetic retinopathy.

OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease, which affects approximately 100,000 people in the United States and Europe combined.

Researchers at Washington University School of Medicine in St. Louis for years have worked to understand the rare condition known as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.

OCU400 is a gene-agnostic modifier gene therapy product based on nuclear hormone receptor (NHR) gene, NR2E3.

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Researchers from the Case Western Reserve University School of Medicine and the Cole Eye Institute have found that supplement melatonin could be linked to a decreased risk of age-related macular degeneration.

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than the standard bimonthly aflibercept control group at all 6 time points through Week 24.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid zone mapping at week 48.

The company noted its OCT reference database now offers a library of 870 healthy eyes, more than tripling the previous versions.

The electromagnetic driving systems are proposed for the flexible 5-DOF magnetic manipulation of a micro-robot within the posterior eye, enabling precise targeted drug delivery.